3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
15
Ovarian Neoplasms
3
Colorectal Neoplasms
3
Neoplasms, Unknown Primary
2
Hereditary Breast and Ovarian Cancer Syndrome
2
Carcinoma, Intraductal, Noninfiltrating
2
Brain Neoplasms
2
Women Age 35+ Qualifies if >15% Lifetime Risk of Breast Cancer as Defined by IBIS Version 8
1
Urogenital Neoplasms
1
Primary Ovarian Insufficiency
1
Neoplastic Syndromes, Hereditary
1
Neoplasm Metastasis
1
Hot Flashes
1
Head and Neck Neoplasms
1
HER2-positive Breast Cancer
1
Digestive System Neoplasms
1
Depression
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Central Nervous System Neoplasms
1
Cardiovascular Diseases
1
Breast Screening
1
Breast Neoplasms, Male
1
Breast Carcinoma In Situ
1
Anatomic Stage II Breast Cancer AJCC v8
1
Anatomic Stage I Breast Cancer AJCC v8
1
Interventions
Trastuzumab
33
pertuzumab
18
Docetaxel
16
pyrotinib
15
Paclitaxel
7
Capecitabine
6
tucatinib
5
Carboplatin
5
Ado-Trastuzumab Emtansine
4
trastuzumab deruxtecan
3
neratinib
3
atezolizumab
2
Protons
2
Neoadjuvant Therapy
2
Fulvestrant
2
pegfilgrastim
1
palbociclib
1
margetuximab
1
liposomal doxorubicin
1
inavolisib
1
exemestane
1
envafolimab
1
dalpiciclib
1
Taxoids
1
Metformin
1
Leuprolide
1
Letrozole
1
Isovaleryl-CoA Dehydrogenase
1
Injections
1
Hospital Information Systems
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
HER2-positive Breast Cancer
×
Genetic Testing
×
Breast
×
Clear all
NCT04638725
2026-06-04
SIGHER
Centre Paul Strauss
Recruiting
9,000 enrolled